Cognition relates to an individual’s thinking, learning and memory processes, and can change over time. Memory and cognitive changes in people with MS can be part of the relapse cycles in RRMS or can be gradual in onset and possibly progressive over time. In both these cases a sensitive and reliable test to measure cognitive function would be of use to detect cognitive change, monitor progress, and to identify significant cognitive impairment as early as possible so that treatment can be adjusted. The study that we are conducting will determine whether new computer-based tests can be used easily in a MS clinic and whether the testing can also be reliably done at home.
We would like to collect cognitive performance data over time from both people with MS and people without MS. This is important as comparing the results between people with and without MS helps us to understand how accurate the test is.
Research has shown a relationship between higher levels of brain iron, the presence of the Alzheimer’s protein, amyloid, and poorer memory and language skills. The purpose of this study is to test the effects of Deferiprone on your disease.
This study aims to see how effective a new blood test (using a diagnostic test called EUROIMMUN biochip) is in diagnosing and monitoring autoimmune blistering skin diseases, in comparison to the standard blood test.
Participants will be asked to donate an additional sample of blood which will be used for research into genetic susceptibility to autoimmune blistering skin disease. Only one visit is required and this usually will occur at the time of your visit at The Royal Melbourne Hospital.
This post-market study involves collecting information for an already approved VNS device. This type of study is conducted for many medications or medical devices to get detailed information about the outcomes of people receiving an approved treatment.
People participating in this study must be deemed appropriate for VNS treatment by their treating doctors and be planned for surgery at The Royal Melbourne Hospital.
The purpose of this study is to better understand the following areas of health for people who receive VNS treatment:
- Anti-epileptic treatment and medication taken by people who have had a VNS device implanted
- Frequency and severity of seizures
- Quality of life and quality of sleep (reported through questionnaires)
- What types of healthcare services are being used
- Details of the settings used on the VNS device
The research study is testing a new treatment for vascular dementia (VaD) and Alzheimer’s disease with cerebrovascular disease. The new treatment is called Sailuotong (SLT). SLT is an extract of three standardised Chinese herbs, Ginseng, Ginkgo and Saffron, all of which are individually permitted for over-the-counter sale in Australia.
The primary objective is to determine the effectiveness of the herbal intervention on cognitive function (the brain functions relating to attention, memory, judgement, reasoning, problem solving etc.), activities of daily living and quality of life, and monitor the safety and effectiveness of SLT.
This research project is testing a new treatment for locally advanced or metastatic ER-positive breast cancer. The new treatment is called venetoclax given in combination with fulvestrant and we we want to know whether adding venetoclax will add to the effectiveness of the fulvestrant.
Fulvestrant is a drug that is designed to bind to the oestrogen receptors, completely blocking the ability of oestrogen to attach to these receptors. This can help to slow down the growth of ER-positive breast cancer.
Venetoclax has been approved for treatment of a type of leukaemia. In this study, venetoclax is an experimental drug, which means health authorties have not approved it in combination with fulvestrant for the treatment of ER-positive breast cancer.
This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits.
Anticipated date enrolment will close: June 2020
An early feasibility study of the safety of the Stentrode™ device in participants with loss of motor function due to paralysis from spinal cord injury, motor neuron disease, stroke, muscular dystrophy or loss of limbs.